Abstracts

ANTIVIRAL ACTIVITY OF LENACAPAVIR AGAINST HIV-2 ISOLATES

Background: Lenacapavir (LEN) is a first-in-class, multistage inhibitor of HIV-1 capsid function in clinical development that was recently approved in the European Union for use in adults with multidrug-resistant HIV-1 infection. LEN is highly potent against HIV-1 in vitro and maintains wild-type activity across HIV-1 isolates with resistance to all existing drug classes. In clinical…

DIVERGENT NEUROIMMUNE SIGNATURES AND HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS SURVIVAL

Background: HIV-associated cryptococcal meningitis caused by Cryptococcus neoformans causes 15-19% of HIV-related deaths globally. Underlying immune modulated mechanisms to be advanced to improve host survival on antifungal treatment was the challenge. We hypothesized that host immune response at diagnosis predicts host survival on antifungal treatment. Methods: In a cohort of HIV+ adults with cryptococcal meningitis,…

SEX-SPECIFIC ASSOCIATION BETWEEN IL-6 AND DEPRESSION IN PERSONS WITH AND WITHOUT HIV

Background: Persons with HIV (PWH) have elevated prevalence of depression compared to persons without HIV (PWoH), and elevated plasma inflammatory biomarkers. Inflammation and depressive symptoms are known to be linked, including in PWH; however, it is unclear whether these associations differ by HIV serostatus and biological sex. Methods: Six plasma inflammatory biomarkers were assessed using…

NON-CLASSICAL MONOCYTES CORRELATE NEGATIVELY WITH HIV-ASSOCIATED COGNITIVE PERFORMANCE

Background: Despite anti-retroviral treatment (ART), people living with HIV (PLWH) are more susceptible to cerebral small vessel disease (CSVD) and subsequent neurocognitive impairment. Altered blood brain barrier (BBB) and transmigration of inflammatory monocytes are risk factors for developing CSVD. Our group has shown that interaction with activated platelets, drives monocytes towards proinflammatory, promigratory phenotype in…